the Pezcoller Lecture 2021 at NIBIT annual Meeting

The XIX NIBIT Meeting 2021, on "Cancer Immunity and Immunotherapy Beyond COVID-19" (October 14-15, 2021) was held virtually, and brought together top clinicians and scientists to discuss new concepts in cancer immunology such as trained immunity, cancer and immune metabolism, and virus-based therapeutic platforms at the intersection of cancer and COVID-19. Updates on cutting-edge therapies in hematologic and solid tumors such as melanoma, lung, breast, prostate, head and neck, and many others were also reported.

The Pezcoller Lecture at the 2021 NIBIT meeting was given by Dr. Nicholas P. Restifo, who was introduced by NIBIT President Mario Paolo Colombo. Dr. Restifo is an American immunologist and physician in cancer immunotherapy. Until July 2019, he was a tenured senior investigator in the National Cancer Institute of the National Institutes of Health in Bethesda, Maryland. He is now the executive vice president of research at Lyell based in San Francisco. His talk "An engineered IL-2 partial agonist promotes CD8+ T cell stemness" was preceded by a brief presentation by the Pezcoller Foundation.

Dr Padmanee Sharma 2019: Dr Padmanee Sharma: From the clinic to the lab: investigating response and resistance mechanisms to immune checkpoint therapy 
Dr Andrew Pardoll 2020: Dr Andrew Pardoll: Applying the MANAFEST platform to analyze neoantigen-specific and coronavirus-specific T cell responses at the clonal level 
unchecked checked